The generic and biosimilar plan "requires incentives and value purchases"

El Generic and Biosimilar Medicines Plan, paralyzed for more than a year due to the health emergency caused by the covid-19 coronavirus, is being finalized to be taken to the Interterritorial Council of the National Health System (CISNS) for your approval. This project has voices for and against. The subject matter expert Joaquín Rodrigo, general director of Sandoz Iberia and president of the Spanish Association of Biosimilars (Biosim), analyzes the project and considers that specific measures should be added, such as profit sharing systems or
value-based acquisition models.

READ MORE